Recent Progress of Oridonin and Its Derivatives for the Treatment of Acute Myelogenous Leukemia

Mini Rev Med Chem. 2020;20(6):483-497. doi: 10.2174/1389557519666191029121809.

Abstract

First stage human clinical trial (CTR20150246) for HAO472, the L-alanine-(14-oridonin) ester trifluoroacetate, was conducted by a Chinese company, Hengrui Medicine Co. Ltd, to develop a new treatment for acute myelogenous leukemia. Two patents, WO2015180549A1 and CN201410047904.X, covered the development of the I-type crystal, stability experiment, conversion rate research, bioavailability experiment, safety assessment, and solubility study. HAO472 hewed out new avenues to explore the therapeutic properties of oridonin derivatives and develop promising treatment of cancer originated from naturally derived drug candidates. Herein, we sought to overview recent progress of the synthetic, physiological, and pharmacological investigations of oridonin and its derivatives, aiming to disclose the therapeutic potentials and broaden the platform for the discovery of new anticancer drugs.

Keywords: HAO472; Oridonin; acute myelogenous leukemia; cytotoxic effects; pharmacology; structural modification..

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents, Phytogenic / chemistry
  • Antineoplastic Agents, Phytogenic / therapeutic use*
  • Diterpenes, Kaurane / chemistry*
  • Diterpenes, Kaurane / therapeutic use*
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Molecular Structure

Substances

  • Antineoplastic Agents, Phytogenic
  • Diterpenes, Kaurane
  • oridonin